MIRM Mirum Pharmaceuticals Inc - Ordinary Shares

19.26
+0.05  (+0%)
Previous Close 19.21
Open 18.68
Price To Book
Market Cap 442,787,150
Shares 22,989,987
Volume 98,186
Short Ratio
Av. Daily Volume 445,211
Stock charts supplied by TradingView

NewsSee all news

  1. Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

    MENLO PARK, Calif., Jan. 16, 2020 /PRNewswire/ -- Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital

  2. Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements

  3. Mirum Pharmaceuticals Announces Pricing of Public Offering

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public

  4. Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

    FDA Requested Change from Type-C Meeting to pre-NDA Meeting Company Plans to Initiate Rolling NDA Submission in Third Quarter 2020 Rare Pediatric Disease Designation Granted for Maralixibat for Alagille

  5. Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it will provide a regulatory

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 4Q 2020.
Maralixibat - MARCH
Progressive Familial Intrahepatic Cholestasis (PFIC)
Rolling NDA to be filed 3Q 2020.
Maralixibat
Alagille Syndrome (ALGS)
Phase 2 trial to be initiated 2020 with data due 2022.
Volixiba
Cholestatic liver diseases

Latest News

  1. Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

    MENLO PARK, Calif., Jan. 16, 2020 /PRNewswire/ -- Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital

  2. Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements

  3. Mirum Pharmaceuticals Announces Pricing of Public Offering

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public

  4. Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

    FDA Requested Change from Type-C Meeting to pre-NDA Meeting Company Plans to Initiate Rolling NDA Submission in Third Quarter 2020 Rare Pediatric Disease Designation Granted for Maralixibat for Alagille

  5. Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it will provide a regulatory

  6. Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that

  7. Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

    Statistically and clinically significant effects on pruritus, xanthomas and growth maintained for up to four years of treatment in Alagille syndrome Durable multi-parameter treatment response and correlation of

  8. Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

    Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted Cash, Cash Equivalents and Investments Balance of $153.6 million Mirum Pharmaceuticals, Inc.

  9. Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the U.S. Food and Drug

  10. Durability of Treatment Effect of Mirum Pharmaceuticals' Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that

  11. Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that

  12. Company Profile for Mirum Pharmaceuticals

    Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead

  13. Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that